Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.

被引：0
|
作者：
Ji, Ke
Bu, Zhaode
Yang, Heli
Wang, Zhenning
Liu, Funan
Liang, Pin
Dong, Yan
Zhang, Jie
Zhao, Qun
Liu, Yang
Ji, Jiafu
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Minist Educ, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[3] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
[4] First Hosp China Med Univ, Shenyang, Peoples R China
[5] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[6] Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
[7] Fourth Hosp Hebei Med Univ, Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
343
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [1] S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer
    Sawasaki, Miyuki
    Tsubamoto, Hiroshi
    Nakamoto, Yoshihiko
    Kakuno, Ayako
    Sonoda, Takashi
    ANTICANCER RESEARCH, 2020, 40 (02) : 991 - 997
  • [2] Nab-paclitaxel plus S-1 followed by S-1 maintenance therapy as a first-line strategy for advanced pancreatic adenocarcinoma.
    Shi, Yan
    Yan, Huan
    Li, Jie
    Lv, Yao
    Han, Quanli
    Wang, Zhikuan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Nab-paclitaxel plus S-1 as first-line treatment in patients with advanced pancreatic adenocarcinoma.
    Shi, Yan
    Yan, Huan
    Han, Quanli
    Nie, Yongkang
    Lv, Yao
    Wang, Zhikuan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer.
    Nakamoto, Yoshihiko
    Tsubamoto, Hiroshi
    Sawazaki, Miyuki
    Kakuno, Ayako
    Sonoda, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study)
    Nakamura, Masaki
    Ojima, Toshiyasu
    Katsuda, Masahiro
    Hayata, Keiji
    Kitadani, Junya
    Nakamori, Mikihito
    Yamaue, Hiroki
    ONCOLOGY, 2021, 99 (01) : 57 - 61
  • [6] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [7] S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
    Xia, Yu
    Zhu, Chenglou
    Xu, Lei
    Yao, Jibin
    Da, Mingxu
    CHINESE MEDICAL JOURNAL, 2022, 135 (18) : 2261 - 2263
  • [8] S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
    Xia Yu
    Zhu Chenglou
    Xu Lei
    Yao Jibin
    Da Mingxu
    中华医学杂志英文版, 2022, 135 (18)
  • [9] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [10] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
12345